Marine Natural Products: A Potential Source of Anti-hepatocellular Carcinoma Drugs
Marine Natural Products: A Potential Source of Anti-hepatocellular Carcinoma Drugs
复制标题
DOI：
10.1021/acs.jmedchem.0c02026
复制
发表时间：
2021-06-15
影响因子：
7.3
通讯作者：
Qian, Qun
中科院分区：
文献类型：
--
作者：
Ren, Xianghai;Xie, Xiaoyu;Qian, Qun
肝细胞癌具有较高的相关发病率和死亡率。虽然化学药物治疗是主要的肝细胞癌治疗策略，但低应答率和治疗耐药性降低了其疗效。因此，迫切需要寻找新的有效药物，许多研究人员试图从海洋生物中寻找新的抗癌药物。海洋种群被认为是具有不同化学结构的独特抗癌化合物的“蓝色药库”。在这里，我们讨论海洋衍生化合物，包括PM060184和Bryostatin1，在体外或体内显示出抗癌活性。基于海洋来源(海绵、藻类、珊瑚、细菌和真菌)，我们介绍了化合物的药理参数、诱导的细胞毒性、对细胞凋亡和转移的影响以及潜在的分子机制。总而言之，这篇综述提供了迄今为止在海洋天然产物和海洋衍生化合物领域进行的抗肝癌研究的见解，以及这些化合物的潜在药理机制和它们在药物开发中的地位。
Hepatocellular carcinoma (HCC) has high associated morbidity and mortality rates. Although chemical medication represents a primary HCC treatment strategy, low response rates and therapeutic resistance serve to reduce its efficacy. Hence, identifying novel effective drugs is urgently needed, and many researchers have sought to identify new anticancer drugs from marine organisms. The marine population is considered a "blue drug bank" of unique anti-cancer compounds with diverse groups of chemical structures. Here, we discuss marine-derived compounds, including PM060184 and bryostatin1, with demonstrated anti-cancer activity in vitro or in vivo. Based on the marine source (sponges, algae, coral, bacteria, and fungi), we introduce pharmacological parameters, compound-induced cyt otoxicity, effects on apoptosis and metastasis, and potential molecular mechanisms. Cumulatively, this review provides insights into anti-HCC research conducted to date in the field of marine natural products and marine-derived compounds, as well as the potential pharmacological mechanisms of these compounds and their status in drug development.